Online inquiry

IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ6255MR)

This product GTTS-WQ6255MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	YP_308669.1
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3654620
UniProt ID	Q9Q0U6

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6255MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ5924MR	IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	CK-301
GTTS-WQ9800MR	IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	JS002
GTTS-WQ5028MR	IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	CA Exendin-4
GTTS-WQ15832MR	IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	XmAb-18087
GTTS-WQ10088MR	IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	L19TNF
GTTS-WQ13616MR	IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	R1450
GTTS-WQ15540MR	IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	UNII-52G405U1E5
GTTS-WQ10559MR	IVTScrip™ mRNA-Anti-IL23A, LY3074828(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	LY3074828

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST